{"type":"trials","record":{"id":42229,"source_id":"clinicaltrials-gov","external_id":"NCT04643886","title":"A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration","brief_summary":"This study is designed to investigate the safety, PK/PD, biomarker and early clinical effects of repeat GEM103 IVT injections.","overall_status":"Terminated","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Gemini Therapeutics, Inc.","enrollment":62,"countries":["United States"],"start_date":"2020-07-30","completion_date":"2022-03-21","last_update_date":"2022-09-23","source_url":"https://clinicaltrials.gov/study/NCT04643886","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Gemini Therapeutics, Inc.","interventions":["GEM103"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Safety of intravitreal (IVT) injections of GEM103, as measured by number of subjects with ocular adverse events. — 18 m…","To describe the clinical effect of GEM103 IVT injection, as the change from baseline in best corrected visual acuity (B…","To evaluate the total CFH levels in aqueous humor after GEM103 IVT injection, whenever possible. — 6 months"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Dry Age-related Macular Degeneration","Geographic Atrophy","Macular Degeneration","Retinal Disease","Retinal Degeneration","GEM103"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04643886","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2020-07-30 to 2022-03-21","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.938Z","intervention":["GEM103"],"participants":62,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Safety of intravitreal (IVT) injections of GEM103, as measured by number of subjects with ocular adverse events. — 18 m…","To describe the clinical effect of GEM103 IVT injection, as the change from baseline in best corrected visual acuity (B…","To evaluate the total CFH levels in aqueous humor after GEM103 IVT injection, whenever possible. — 6 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42229","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}